Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy
Synlogic Inc (NASDAQ:SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC:RHHBY) for the discovery of Synthetic Biotic medicine…
Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer
The FDA has accepted for review Agenus Inc’s (NASDAQ:AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer…
Lineage Inks Option Agreement With Amasa Therapeutics For HyStem
Lineage Cell Therapeutics Inc (NYSE:LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to…
PhaseBio Stock Jumps On Bentracimab Commercialization Pact In Europe
PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) has entered into an exclusive licensing agreement with privately-held Alfasigma S.p.A for the commercialization of bentracimab. The…
FibroGen In-Licenses Three HiFiBiO Programs For Cancer, Autoimmune Settings
FibroGen Inc (NASDAQ:FGEN) and HiFiBiO Therapeutics have entered into a licensing agreement for three programs in the immuno-oncology and autoimmune space.…
OPKO Health Offloads Fill and Finish Manufacturing Facility in Ireland To Horizon Therapeutics
OPKO Health Inc’s (NASDAQ:OPK) subsidiary, EirGen Pharma Ltd, has agreed to sell one of its facilities in Waterford, Ireland, to Horizon Therapeutics…
Viking Therapeutics’ VK0214 Shows Encouraging Safety, Tolerability Profile In Healthy Volunteers
Viking Therapeutics Inc (NASDAQ:VKTX) has announced results from its Phase 1 trial of VK0214 in healthy volunteers. VK0214 demonstrated encouraging safety…
Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder
The FDA has granted Fast Track designation to Applied Therapeutics Inc’s (NASDAQ:APLT) AT-007 to treat Galactosemia, a rare metabolic disease. AT-007 is…
Raw Material Shortage Holding Up Novavax’s COVID-19 Shot Manufacturing, Says Serum Institute
Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the Novavax Inc (NASDAQ:NVAX) vaccine…
Pfizer’s Xeljanz Cuts Incidence Of Death, Respiratory Failure In COVID-19 Patients, Brazilian Study Shows
Pfizer Inc (NYSE: PFE) said that its oral rheumatoid arthritis drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s primary goal.